Objective:

To generate support for Aquamin®’s ability to affect gastrointestinal permeability in individuals with ulcerative colitis (UC).

Approach:

Key Findings:

• Baseline urine mannitol levels were 54% higher in UC patients compared to healthy subjects (p = 0.006).
• After 90 days of Aquamin® supplementation, urinary mannitol levels in UC patients decreased by 28%, 26%, and 41% at the 0–2 h, 2–8 h, and 8–24 h time points, respectively; the reduction at the 0–2 h interval reached statistical significance (p = 0.015).
• Total post-intervention mannitol excretion was reduced by 29% (p = 0.024).
• Aquamin® was well tolerated with no serious adverse events reported.
• A modest but statistically significant reduction in alkaline phosphatase levels was observed after 90 days.

Interpretation:

Limitations:

• Small sample size (n = 8 per group).
• Open-label design may introduce bias.

Conclusion:

Sources:

• Clinical Trial Registration
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.